Total
0
Shares
Medibio (ASX:MEB) - Managing Director, Claude Solitario - The Market Herald
Managing Director, Claude Solitario
Source: Cyber Clinic
  • Mental health tech company Medibio (MEB) has been granted a patent by the U.S. Patent and Trademark Office
  • The patent is titled 'Method and System for Monitoring Stress Conditions' and relates machine learning that monitors stress conditions by analysing heart rate data collected before, during and after sleep
  • This patent will be instrumental in protecting Medibio's mental well-being program, ilumen, and its consumer app, which is currently under development
  • Medibio is now in the process of reviewing the scope of existing patents and will advise the market of any findings
  • Company shares are steady on the market this morning and are trading for 1.2 cents each

Mental health tech company Medibio (MEB) has been granted a patent by the U.S. Patent and Trademark Office.

The patent is titled 'Method and System for Monitoring Stress Conditions' and relates machine learning that monitors stress conditions by analysing heart rate data collected before, during and after sleep.

This patent will be instrumental in protecting Medibio's mental well-being program, ilumen, and its consumer app, which currently under development.

ilumen is a program which provides data feedback to help employees improve their mental well-being.

It assesses the user's wellness by conducting surveys which track much sleep they are getting, their exercise patterns and work hours. The user will receive their results with recommendations on coping strategies and a personal development plan.

Medibio is now in the process of reviewing the scope of existing patents and will advise the market of any findings.

Company shares are steady on the market and are trading for 1.2 cents each at 11:19 am AEST.


Subscribe


MEB by the numbers
More From The Market Herald
CardieX (ASX:CDX) - CEO & Managing Director, Craig Cooper - The Market Herald

" CardieX (ASX:CDX) subsidiary granted European blood pressure patent

CardieX’s (CDX) subsidiary, ATCOR, has been granted a new patent by the European Patent Office (EPO) for its SphygmoCor technology.
Immutep (ASX:IMM) - CEO, Marc Voigt - The Market Herald

" Immutep (ASX:IMM) sees improved results from two cancer trials

Cancer treatment company Immutep (IMM) has seen improving results from its cancer trials, INSIGHT-004 and TACTI-002.
Cann Global (CGB) appoints Marion Lesaffre as COO

" Purifloh (ASX:PO3) chairman resigns

Purifloh (PO3) Chairman, Bill Parfet, has announced his resignation from the Chairman position and stepped down as the Director of the Board.
Alt Resources (ASX:ARS)  takeover becomes unconditional

" 5GN Networks’ (ASX:5GN) takeover bid endorsed by Webcentral (ASX:WCG) directors

5G Networks’ (5GN) proposed buy-out bid has won over Webcentral Group’s (WCG) board, despite a competing cash offer from Web.com.